A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Sagar,Sardesai

第一单位： The Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA.

作者： Sagar,Sardesai ^[1] ; Mohamed,Badawi ^[2] ; Ewa,Mrozek ^[3] ; Evan,Morgan ^[1] ; Mitch,Phelps ^[2] ; Julie,Stephens ^[3] ; Lai,Wei ^[4] ; Mahmoud,Kassem ^[1] ; Yonghua,Ling ^[2] ; Maryam,Lustberg ^[1] ; Daniel,Stover ^[1] ; Nicole,Williams ^[1] ; Rachel,Layman ^[5] ; Raquel,Reinbolt ^[1] ; Jeffrey,VanDeusen ^[1] ; Mathew,Cherian ^[1] ; Michael,Grever ^[6] ; William,Carson ^[7] ; Bhuvaneswari,Ramaswamy ^[1] ; Robert,Wesolowski ^[8]

作者单位： The Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA. ^[1] The Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA. ^[2] Medical Oncology, Mercy Health, St. Rita's Cancer Center, Lima, OH, USA. ^[3] The Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA. ^[4] Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[5] The Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, USA. ^[6] The Division of Surgical Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA. ^[7] The Division of Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH, USA. Robert.Wesolowski@osumc.edu.;The Ohio State University Comprehensive Cancer Center, Suite 1204, Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu. ^[8]

关键词 Breast cancer Chemotherapy Gamma secretase Neoadjuvant Notch pathway Pharmacokinetics Phase I clinical trial